Shilpa Medicare gets Health Canada GMP approval for Jadcherla facility

Written by Ruchika Sharma Published On 2022-12-05T12:30:31+05:30 | Updated On 5 Dec 2022 6:54 PM IST

Shilpa Medicare gets Health Canada GMP approval for Jadcherla facility

Karnataka: Shilpa Medicare has recently announced that the Company's finished dosage form manufacturing facility, Unit IV, situated at Pharma SEZ, Jadcherla, Telangana, has received Health Canada GMP approval.

The inspection was conducted from September 12, 2022, to September 16, 2022.

The facility is involved in the manufacturing, packaging, labelling, and testing of finished dosage forms (sterile injections and oral solids) for the treatment of cancer and adjuvant therapy.

This GMP approval will allow the company for the commercial distribution of products in Canada and enable new application submissions to Health Canada.

"This approval reaffirms the company's focused efforts to maintain the GMP status up to the standards of global regulatory authorities," Shilpa Medicare said in a BSE filing.

Shilpa Medicare Limited started its operations as an API manufacturer in 1987 in Raichur, Karnataka- India. Commercial production in the SML was started in November 1989. Today Shilpa Medicare Limited is a global brand in manufacturing and supplying of affordable API and Formulation globally in different regulated markets.

Read also: Shilpa Medicare bags CDSCO nod for topical hemostatic spray of Tranexamic Acid

Shilpa MedicareShilpa Medicare newsJadcherla facilitycancer

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751